Harrow Health, Inc. Aktie News

Doubling of VEVYE® Sales Force is On Track, Expansion of IHEEZO® Commercial Footprint to  the Office-Based Setting Underway, and Doubling TRIESENCE® Commercial Footprint in the Surgical-Based Setting is Proceeding

Harrow, Inc. continues to execute on its branded ophthalmic portfolio, with Vevye and Iheezo outperforming expectations and gaining market share. Despite a slight Q3 revenue miss and lowered 2025 guidance ($270M–$280M), operating leverage and commercial expansion underpin a robust growth outlook. Vevye's preferred formulary status and expanded coverage in 2026, alongside Iheezo's strong adoptio...

Harrow may deliver $265M in 2025 revenue, potentially missing the low end of its revised $270M–$280M guidance. Recent Bloomberg data suggest strong growth in Iheezo and Vevye, but specialty and compounded segments face headwinds and one-time impacts. Considerable uncertainty exists due to data limitations and ASP uncertainty.

Biotech stock Harrow is in a cup base with a buy point of 50.72 after third-quarter results.

The Undercovered Dozen spotlights 12 lesser-known stocks and funds with compelling investment theses and recent developments. This week's edition covers articles published between Nov. 28 and Dec. 4, offering fresh investment ideas. The series aims to inspire discussion and help investors discover overlooked opportunities in the market.

Philadelphia-based Penn Capital Management added 325,478 shares of Harrow for an estimated $15.7 million in the third quarter. The move created a new position for Penn, which did not report holding any shares of Harrow in the previous quarter.

NASHVILLE, Tenn., Nov. 24, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following two investor conferences in December: BTIG 5 th Annual Ophthalmology Day (Virtual) Format: Fireside chatDate/Time: Monday, December 1, 2025, at 8:30 AM EST Piper Sandler 37 th ...

NASHVILLE, Tenn., Nov. 18, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that it has completed the acquisition of Melt Pharmaceuticals, Inc. (Melt), a clinical-stage pharmaceutical company pioneering non-opioid, non-IV therapies for sedation for medical procedures in the hospital, outpatient, and i...